Cervical Imaging System Improves Detection of High-Grade Precancerous Lesions

A new cervical imaging system has been developed to significantly improve the detection of high-grade precancerous cervical abnormalities that have the potential to become invasive cancer.

SpectraScience, Inc. (San Diego; CA, USA), a medical device company, announced that it would place its LUMA cervical imaging system to detect precancers at Minnesota Gynecology and Surgery (Edina, MN, USA). Dr. James B. Presthus, cofounder of Minnesota Gynecology and Surgery, stated, "The introduction of the LUMA system represents our continued dedication in providing the best care possible for our patients. The LUMA system gives our practice a unique and powerful tool when following up on abnormal Pap test results. We have always been on the leading edge of new technologies, and with the LUMA system our patients will experience improved outcomes from earlier detection of precancers of the cervix and, therefore, earlier treatment. For the first time, this device gives us objective tissue diagnosis capability as compared to today's subjective interpretation methods. We are the first practice in Minnesota to offer the noninvasive LUMA test.”

The LUMA system provides a safe, noninvasive and effective method, that when used as an adjunct to colposcopy, has been demonstrated to uncover at least 26% more high-grade precancerous disease than colposcopy alone.

SpectraScience has filed for 60 patents worldwide on its WavSTAT optical biopsy system and LUMA cervical cancer imaging system, which are both used to diagnose tissue to determine within seconds if it is normal, precancerous, or cancerous. The WavSTAT and LUMA systems are currently approved by the U.S. Food and Drug Demonstration (FDA) for detecting precancer and cancer in the colon and cervix, and an evaluation for detection of precancers in the throat (Barrett's esophagus) is being tested.

SpectraScience is a medical device company that designs, develops, manufactures, and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT optical biopsy system utilizes light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the United States, and the CE Marking for the European Union, the WavSTAT system is the first commercially available product that incorporates this innovative technology for clinical use. The company's LUM cervical imaging technology has received FDA approval as an optical noninvasive system that is proven to more effectively detect cervical cancer precursors than current conventional methods available.

Related Links:
Spectra Science